MedTrace Logo

Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes

NCT06293664 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-03-05

No results posted yet for this study

Summary

Alpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland. It acts as an agonist to the melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and disposal. This study aims to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus (T2DM).

Conditions

Interventions

OTHER

α-MSH infusion

Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

OTHER

Placebo solutions

Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.

Sponsors & Collaborators

  • Dasman Diabetes Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2024-04-04
Completion
2024-04-04

Countries

  • Kuwait

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06293664 on ClinicalTrials.gov